Área Cardiovascular

Grupo de Investigación cardiometabólica en atención primaria

Jorge Navarro Pérez

Doctor en Medicina ,“cum laude”, por la Universidad de Valencia, es especialista en Medicina Familiar y Comunitaria.

Su labor docente está vinculada al Departamento de Medicina de la Universidad de Valencia, siendo el responsable de la asignatura Atención Primaria y Geriatría.

Su labor investigadora se desarrolla en el terreno de la investigación caridometabólica, siendo el investigador principal del grupo de cardiometabolismo de atención primaria del Instituto de Investigación Sanitaria INCLIVA. Además, es miembro del CIBER de Salud Pública (CIBERESP).

Es miembro activo de la Sociedad Española de Medicina Familiar y Comunitaria ,SEMFYC en el grupo de trabajo de diabetes, el Observatorio de enfermedades crónicas, Programa de Actividades Preventivas y de Promoción de la Salud-PAPPS, de la Sociedad Valenciana de Medicina Familiar y Comunitaria, SVMFYC, como coordinador del grupo de diabetes, de la RedGEDAPS  de la que es coordinador autonómico y de la Sociedad Española de Diabetes, SED en el grupo de trabajo de enfermedad cardiovascular.

Su labor en gestión incluye un Master Universitario en Dirección y Organización de Hospitales y Servicios de Salud por la Universidad Politécnica de Valencia, habiendo sido subdirector médico del Hospital La Fe y director médico del Hospital Clínico de Valencia. 

 

Grupo de Investigación Cardiometabólica en Atención Primaria

Investigador colaborador

Alvaro Bonet Pla
Carlos Fluixá Carrascosa
José Sanfélix-Genovés
Jose Vicente Lozano Vidal
José Luis Trillo Mata

Investigadora colaboradora

Nidia Ruiz Varea
Pilar Roca Navarro
Victoria Gosalbes Soler
Ruth Usó Talamantes
  • Consolidar líneas de investigación previas.
  • Colaborar en un proyecto institucional multidisciplinar en el seno del INCLIVA.
Número total de publicaciones: 40. Factor de Impacto acumulado: 110.56
The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype
Vinué Á, Navarro J, Herrero-Cervera A, García-Cubas M, Andrés-Blasco I, Martínez-Hervás S, Real JT, Ascaso JF, González-Navarro H.
Diabetología. 2017 Sep. 1801-1812. FI: 6.206
Saxagliptin and Heart Failure in the SAVOR-TIMI 53 Trial: Reflections on the Bradford Hill Criteria.
Cebrián Cuenca AM, Orozco Beltrán D, Navarro Pérez J, Álvarez-Guisasola F, Núñez Villota J, Consuegra-Sánchez L.
Revista española de cardiología. 2017 Dec. 1143-1144. FI: 4.485
Erratum to: Pharmaceutical cost management in an ambulatory setting using a risk adjustment tool.
Vivas-Consuelo D, Usó-Talamantes R, Guadalajara-Olmeda N, Trillo-Mata JL, Sancho-Mestre C, Buigues-Pastor L.
BMC health services research. 2017 Mar 31. 244. FI: 1.827
Clinical applicability and cost-effectiveness of DIABSCORE in screening for type 2 diabetes in primary care
Rodríguez-Pérez MC, Orozco-Beltrán D, Gil-Guillén V, Domínguez-Coello S, Almeida-González D, Brito-Díaz B, Marcelino-Rodríguez I, Carratalá-Munuera MC, Gómez-Moreno N, Navarro-Perez J, Brotons-Munto F, Pertusa-Martinez S, Cabrera de León A.
Diabetes research and clinical practice. 2017 Aug. 0168-8227. FI: 3.639
Implementation of strategies and tools of sociosanitary coordination in a health department.
Botija P, Botija M, Navarro J.
Gaceta sanitaria. 2017 Sep 25. . FI: 1.768
Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: The ESCARVAL-RISK study
Orozco-Beltran D1, Gil-Guillen VF1, Redon J2,3,4, Martin-Moreno JM5, Pallares-Carratala V6, Navarro-Perez J2,3,7, Valls-Roca F8, Sanchis-Domenech C9, Fernandez-Gimenez A10, Perez-Navarro A10, Bertomeu-Martinez V11,12, Bertomeu-Gonzalez V11,12, Cordero A11,12, Pascual de la Torre M13, Trillo JL14, Carratala-Munuera C1, Pita-Fernandez S15, Uso R16, Durazo-Arvizu R17, Cooper R17, Sanz G18, Castellano JM18,19, Ascaso JF20,21, Carmena R20,21, Tellez-Plaza M22,23; ESCARVAL Study Group.
PloS one. 2017 Oct 18. e0186196. FI: 2.806
Complexity Levels in Patients With Heart Failure Diagnostic Codes in a Population
Navarro J, Calabuig J, Usó R, Redón J, Sanchis J, Núñez J
Revista española de cardiología (English ed.). 2017 Jul 25. S1885-5857(17)30272-4. FI: 4.485
Primary and secondary non-adherence to osteoporotic medications after hip fracture in Spain. The PREV2FO population-based retrospective cohort study
García-Sempere A, Hurtado I, Sanfélix-Genovés J, Rodríguez-Bernal CL, Gil Orozco R, Peiró S, Sanfélix-Gimeno G.
Scientific reports. 2017 Sep 18. 11784. FI: 4.259
Saxagliptin and risk of heart failure hospitalization: Concern or miscalculation?
Cebrián-Cuenca AM, Orozco-Beltrán D, Navarro-Pérez J, Franch-Nadal J, Núñez-Villota J, Consuegra-Sánchez L
International journal of cardiology.. 2016 Jun 29. 573-574. FI: 4.638
Renal function and attributable risk of death and cardiovascular hospitalization in patients with cardiovascular risk factors from a registry-based cohort: the Estudio Cardiovascular Valencia-risk study.
Tellez-Plaza M, Orozco-Beltran D, Gil-Guillen V, Pita-Fernandez S, Navarro-Pérez J, Pallares V, Valls F, Fernandez A, Perez-Navarro AM, Sanchis C, Dominguez-Lucas A, Martin-Moreno JM, Redon J, ESCARVAL STUDY GROUP.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension.. 2016 Nov. 2266-73. FI: 5.062
Diabetes mellitus and cardiovascular risk: Working group recommendations of Diabetes and Cardiovascular Disease of the Spanish Society of Diabetes (SED, 2015).
Arrieta F, Iglesias P, Pedro-Botet J, Tébar FJ, Ortega E, Nubiola A, Pardo JL, Maldonado GF, Obaya JC, Matute P, Petrecca R, Alonso N, Sarabia E, Sánchez-Margalet V, Alemán JJ, Navarro J, Becerra A, Duran S, Aguilar M, Escobar-Jiménez F, Grupo de Trabajo Diabetes y Enfermedad Cardiovascular de la Sociedad Española de Diabetes (SED)
Atencion primaria. 2016 May. 325-36. FI: 0.953
Impact of hypertension on mortality and cardiovascular disease burden in patients with cardiovascular risk factors from a general practice setting: the ESCARVAL-risk study.
Redon J, Tellez-Plaza M, Orozco-Beltran D, Gil-Guillen V, Pita Fernandez S, Navarro-Pérez J, Pallares V, Valls F, Fernandez A, Perez-Navarro AM, Sanchis C, Dominguez-Lucas A, Sanz G, Martin-Moreno JM, ESCARVAL Study Group
Journal of hypertension. Supplement : official journal of the International Society of Hypertension.. 2016 Jun. 1075-83. FI: 5.062
Knowledge level of hypertensive patients about hypertension. Relationship between knowledge level and hypertension control.
Benítez Camps M, Egocheaga Cabello MI, Dalfó Baqué A, Bajo García J, Vara González L, Sanchis Doménech C, Martín Rioboo E, Ureña Fernández T, Domínguez Sardiña M, Bonet Pla A, nombre del equipo investigador del trabajo
Hipertensión y riesgo vascular.. 2015 Jan-Mar. 44166
3A.05: Hypertension and risk of events associated to reduced EGFR. The escarval-risk study.
Tellez-Plaza M, Orozco-Beltran D, Gil-Guillen V, Navarro-Pérez J, Pallares V, Valls F, Fernandez A, Martin-Moreno JM, Sanchis C, Dominguez-Lucas A, Redon J
Journal of hypertension. 2015 Jun. e32-3. FI: 4.72
A cardiovascular educational intervention for primary care professionals in Spain: positive impact in a quasi-experimental study.
Gil-Guillén V, Hermida E, Pita-Fernandez S, Palazon-Bru A, Durazo-Arvizu R, Pallares-Carratala V, Orozco-Beltran D, Carratala-Munuera C, Lopez-Pineda A, Navarro J
The British journal of general practice : the journal of the Royal College of General Practitioners. 2015 Jan. e32-40. FI: 2.294
A decision dilemma: Cushing syndrome during pregnancy.
Darocas M, Ruiz N, Bergoglio MT, Cano A
Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2015 Jan. 93-4. FI: 0.551
Diabetes mellitus and cardiovascular risk: Working group recommendations of Diabetes and Cardiovascular Disease of the Spanish Society of Diabetes (SED, 2015).
Arrieta F, Iglesias P, Pedro-Botet J, Tébar FJ, Ortega E, Nubiola A, Pardo JL, Maldonado GF, Obaya JC, Matute P, Petrecca R, Alonso N, Sarabia E, Sánchez-Margalet V, Alemán JJ, Navarro J, Becerra A, Duran S, Aguilar M, Escobar-Jiménez F, Grupo de Trabajo Diabetes y Enfermedad Cardiovascular de la Sociedad Española de Diabetes (SED)
Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis.. 2015 Jul-Aug. 181-92
Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia.
Saumell S, Florensa L, Rodríguez-Rivera M, Pedro C, Hernández-Rivas JM, Lumbreras E, Abáigar M, Collado R, Ivars D, Carbonell F, Marugán I, Tormo M, Botia M, Piñan MÁ, Ancín I, González T, Varela ND, Grau J, Granada I, Ruiz N, Martín ML, Fernández-Guijarro M, Duarte JJ, Calasanz MJ, Larrayoz MJ, Solé F
Leukemia & lymphoma. 2015 Jan. 242-3. FI: 2.891
Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment.
Martínez MT, González I, Tarazona N, Roselló S, Saiz R, Sanmartín A, Martínez-Agulló Á, Caballero A, Mas P, Franco J, Martínez-Jabaloyas J, García-Callejo J, Martín V, Navarro J, Teruel A, Lluch A, Chirivella I
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2015 Feb. 167-72. FI: 2.077
Overuse and Underuse of Antiosteoporotic Treatments According to Highly Influential Osteoporosis Guidelines: A Population-Based Cross-Sectional Study in Spain.
Sanfélix-Gimeno G, Hurtado I, Sanfélix-Genovés J, Baixauli-Pérez C, Rodríguez-Bernal CL, Peiró S
PloS one. 2015. e0135475. FI: 3.234
Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment.
Morillas C, Feliciano R, Catalina PF, Ponte C, Botella M, Rodrigues J, Esmatjes E, Lafita J, Lizán L, Llorente I, Morales C, Navarro-Pérez J, Orozco-Beltran D, Paz S, Ramirez de Arellano A, Cardoso C, Tribaldos Causadias M
Patient preference and adherence. 2015. 1443-58. FI: 1.676
Primary Non-Adherence to Antiosteoporotic Treatment and Associated Factors: A Prospective Cohort Study in Spain.
Hurtado I, Sanfélix-Gimeno G, Peiró S, Sanfélix-Genovés J
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.. 2015 Nov. A650. FI: 3.279
Rationale and study design for an individualized perioperative open lung ventilatory strategy (iPROVE): study protocol for a randomized controlled trial.
Ferrando C, Soro M, Canet J, Unzueta MC, Suárez F, Librero J, Peiró S, Llombart A, Delgado C, León I, Rovira L, Ramasco F, Granell M, Aldecoa C, Diaz O, Balust J, Garutti I, de la Matta M, Pensado A, Gonzalez R, Durán ME, Gallego L, Del Valle SG, Redondo FJ, Diaz P, Pestaña D, Rodríguez A, Aguirre J, García JM, García J, Espinosa E, Charco P, Navarro J, Rodríguez C, Tusman G, Belda FJ, iPROVE investigators (Appendices 1 and 2).
Trials. 2015 Apr 27. 193. FI: 1.731
The CHADS2 Score to Predict Stroke Risk in the Absence of Atrial Fibrillation in Hypertensive Patients Aged 65 Years or Older.
Morillas P, Pallarés V, Fácila L, Llisterri JL, Sebastián ME, Gómez M, Castilla E, Camarasa R, Sandin M, García-Honrubia A, FAPRES registry investigators
Revista espanola de cardiologia (English ed.). 2015 Jun. 485-91
Is the physician's behavior in dyslipidemia diagnosis in accordance with guidelines? Cross-sectional ESCARVAL study.
Palazón-Bru A, Gil-Guillén VF, Orozco-Beltrán D, Pallarés-Carratalá V, Valls-Roca F, Sanchís-Domenech C, Martín-Moreno JM, Redón J, Navarro-Pérez J, Fernández-Giménez A, Pérez-Navarro AM, Trillo JL, Usó R, Ruiz E
PloS one. 2014. e91567. FI: 3.534
Variability in the recommendations for the clinical management of osteoporosis.
Sanfélix-Genovés J, Catalá-López F, Sanfélix-Gimeno G, Hurtado I, Baixauli C, Peiró S
Medicina clinica. 2014 Jan 7. 15-22. FI: 1.252
Quality of care indicators for benign prostatic hyperplasia. A qualitative study.
Navarro-Pérez J, Peiró S, Brotons-Muntó F, López-Alcina E, Real-Romaguera A, en nombre del Grupo de trabajo del Programa de Formación e Investigación en Hiperplasia Benigna de Próstata de la Comunidad Valenciana
Atencion primaria / Sociedad Española de Medicina de Familia y Comunitaria. 2014 May. 231-7. FI: 0.894
Health promotion and prevention in the economic crisis: the role of the health sector. SESPAS report 2014.
Márquez-Calderón S, Villegas-Portero R, Gosalbes Soler V, Martínez-Pecino F
Gaceta sanitaria / S.E.S.P.A.S. 2014 Jun. 116-23. FI: 1.25
Cardiovascular preventive recommendations.
Maiques Galán A, Brotons Cuixart C, Villar Álvarez F, Martín Rioboó E, Banegas Banegas JR, Navarro Pérez J, Alemán Sánchez JJ, Lobos-Bejarano JM, Ortega Sánchez-Pinilla R, Orozco-Beltrán D, Gil Guillén V
Atencion primaria / Sociedad Española de Medicina de Familia y Comunitaria. 2014 Jun. 42064. FI: 0.894
The PROPRESE trial: results of a new health care organizational model in primary care for patients with chronic coronary heart disease based on a multifactorial intervention.
Ruescas-Escolano E, Orozco-Beltran D, Gaubert-Tortosa M, Navarro-Palazón A, Cordero-Fort A, Navarro-Pérez J, Carratalá-Munuera C, Pertusa-Martínez S, Soler-Bahilo E, Brotons-Muntó F, Bort-Cubero J, Núñez-Martínez MA, Bertomeu-Martínez V, López-Pineda A, Gil-Guillén VF, en nombre de los investigadores del Proyecto PROPRESE
Atencion primaria / Sociedad Española de Medicina de Familia y Comunitaria. 2014 Jun. 42134. FI: 0.894
Appropriateness of clopidogrel use according to current recommendations.
Fornós-Garrigós A, Orozco-Beltrán D, Gil-Guillén VF, Puig-Barberà J, Fluixa C, Fernández A
Family practice. 2014 Dec. 694-8. FI: 1.842
Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial.
Jennings C, Kotseva K, De Bacquer D, Hoes A, de Velasco J, Brusaferro S, Mead A, Jones J, Tonstad S, Wood D, EUROACTION PLUS Study Group
European heart journal. 2014 Jun 1. 1411-20. FI: 14.723
Serum heat shock protein 60 in acute heart failure: a new biomarker?
Bonanad C, Núñez J, Sanchis J, Bodi V, Chaustre F, Chillet M, Miñana G, Forteza MJ, Palau P, Núñez E, Navarro D, Llàcer A, Chorro FJ
Congestive heart failure (Greenwich, Conn.). 2013 Jan. 41918
Barriers associated with poor control in Spanish diabetic patients. A consensus study.
Carratalá-Munuera MC, Gil-Guillen VF, Orozco-Beltran D, Navarro-Pérez J, Caballero-Martínez F, Alvarez-Guisasola F, García-Soidán J, Fluixá-Carrascosa C, Franch-Nadal J, Martín-Rioboó E, Carrillo-Fernández L, Artola-Menéndez S, “Integrated Management of Type 2 Diabetes Mellitus” Research Group
International journal of clinical practice. 2013 Sep. 888-94. FI: 2.427
Use of Drugs Related to the Treatment of Diabetes Mellitus and Other Cardiovascular Risk Factors in the Spanish Population. The Di@bet.es Study.
Rojo-Martínez G, Valdés S, Colomo N, Lucena MI, Gaztambide S, Gomis R, Casamitjana R, Carmena R, Catalá M, Martínez-Larrad MT, Serrano-Ríos M, Castaño L, Vendrell J, Girbés J, Franch J, Vázquez JA, Mora-Peces I, Urrutia I, Pascual-Manich G, Ortega E, Menéndez E, Delgado E, Bordiú E, Castell C, López-Alba A, Goday A, Calle A, Bosch-Comas A, Soriguer F
Revista española de cardiología. 2013 Nov. 854-863. FI: 3.204
Effectiveness of a new health care organization model in primary care for chronic cardiovascular disease patients based on a multifactorial intervention: the PROPRESE randomized controlled trial.
Orozco-Beltran D, Ruescas-Escolano E, Navarro-Palazón AI, Cordero A, Gaubert-Tortosa M, Navarro-Perez J, Carratalá-Munuera C, Pertusa-Martínez S, Soler-Bahilo E, Brotons-Muntó F, Bort-Cubero J, Nuñez-Martinez MA, Bertomeu-Martinez V, Gil-Guillen VF
BMC health services research. 2013 Aug 2. 293. FI: 1.773
Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: A 5,693-patient cross-sectional analysis from Spain.
Gorostidi M, Sarafidis PA, de la Sierra A, Segura J, de la Cruz JJ, Banegas JR, Ruilope LM, Spanish ABPM Registry Investigators
American journal of kidney diseases : the official journal of the National Kidney Foundation. 2013 Aug. 285-94. FI: 5.294
Gazpacho consumption is associated with lower blood pressure and reduced hypertension in a high cardiovascular risk cohort. Cross-sectional study of the PREDIMED trial.
Medina-Remón A, Vallverdú-Queralt A, Arranz S, Ros E, Martínez-González MA, Sacanella E, Covas MI, Corella D, Salas-Salvadó J, Gómez-Gracia E, Ruiz-Gutiérrez V, Lapetra J, García-Valdueza M, Arós F, Saez GT, Serra-Majem L, Pinto X, Vinyoles E, Estruch R, Lamuela-Raventos RM
Nutrition, metabolism, and cardiovascular diseases : NMCD. 2013 Oct. 944-52. FI: 3.978
Prevalence and associated factors in self-monitoring of blood glucose in noninsulin-treated type 2 diabetes patients in the Valencia Community, Spain.
Cano-Blanquer D, Cervera-Casino P, Peiró-Moreno S, Mateu-García M, Barreda-Aznar A, Grupo de Estudio de la Automonitorización Glucémica
Revista española de salud pública. 2013 Mar-Apr. 149-63
Bibliometric analysis of International Scientific production on primary care.
Carratalá-Munuera MC, Orozco-Beltrán D, Gil-Guillen VF, Navarro-Perez J, Quirce F, Merino J, Basora J
Atencion primaria / Sociedad Española de Medicina de Familia y Comunitaria. 2012 Nov. 651-8. FI: 0.957

Revisión sistemática de la eficacia de las intervenciones preventivas cardiometabólicas basadas en el modelo de atención a crónicos (CCM).

Referencia:
02/2011
Investigador/a principal:
Jorge Navarro Pérez
Entidad financiadora:
Generalitat Valenciana. Conselleria de Sanitat
Duración:
19/09/2012 - 19/09/2012
Presupuesto total:
€3.850